Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02965378 · ClinicalTrials.gov registry record · Phase 2
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02965378 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 43 participants.
The verdict
NCT02965378, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the fibroblast growth factor receptor (FGFR) biomarker. FGFR can cause tumor cells to grow more quickly. AZD4547 may decrease the activity of FGFR and may be able to shrink tumors.
Interventions
- DRUG Docetaxel
- OTHER Laboratory Biomarker Analysis
- DRUG FGFR Inhibitor AZD4547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02965378
The ClinicalTrials.gov registry entry for NCT02965378 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT02965378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02965378 about?
NCT02965378 is a clinical study titled "Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer". This phase II/III trial studies how well FGFR inhibitor AZD4547 (AZD4547) works in treating patients with stage IV squamous cell lung cancer that has come back after previous treatment. This is a sub-study that includes all screened patients positive for the fibroblast growth factor receptor (FGFR) ...
What is the current status of trial NCT02965378?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2014-10. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02965378?
The interventions under investigation include: Docetaxel (DRUG), Laboratory Biomarker Analysis (OTHER), FGFR Inhibitor AZD4547 (DRUG).
Who is sponsoring clinical trial NCT02965378?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.